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Materials and Methods

Preparation of lipid/oil mixtures
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC, Avanti Polar Lipids, Alabaster, AL) was dissolved in chloroform (10 mg/ml), dried under gentle nitrogen flow (45 min, 37°C), then dried under vacuum (2 h, room temperature). Dried lipids were dissolved in dodecane or hexadecane with shaking overnight (1 mM, 37°C, 100 rpm).
Device microfabrication and operation
The device was fabricated in polydimethylsiloxane (PDMS) using soft lithography and bonded to glass. Briefly, PDMS pre-polymer was mixed with curing agent (10:1 w/w, SYLGARD 184, Dow Corning, Midland, MI), degassed under vacuum and poured onto the 40-µm-high SU-8 device mold (Stanford Microfluidics Foundry, Stanford, CA). The polymer was cured (1.5 h, 70 °C), removed from the mold, and diced into individual devices.
Reservoirs were created with a biopsy punch (0.75 mm, Harris Uni-Core). Punched devices and borosilicate glass slides were hydrolyzed (5:1:1 water:HCl:H 2 O 2 , 30 min), dried, and placed into contact to bond the PDMS device to the slide. All channels were 40 µm deep.
Prior to the Y-junction, the droplet forming channel was 60 µm wide, the extracellular aqueous channel was 100 µm wide and the phase transfer channel is 200 µm wide (technical device drawings are provided).
Fluids were driven through the circuit with syringe pumps (Harvard Apparatus, Holliston, MA) through micro-bore tygon tubing (0.03 in OD × 0.01 in ID, Saint-Gobain).
Water droplets in oil were formed at a T-junction with a flow rate ratio > 3 (oil:water).
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Droplet flow was delivered to the central channel where a stable two-phase oil/water interface was generated with a co-flowing extracellular aqueous flow (AQ ex ). Using dodecane as the carrier oil phase, cytoplasmic droplet aqueous flow (AQ cy ) was 0.1 µL/min, oil was 2 µL/min, and AQ ex was 2 µL/min.
Vesicle characterization and imaging
Droplets containing Cascade Blue−labeled dextran (1% w/w, 10 kDa, Invitrogen, Carlsbad, CA) and fluorescein dye (10 µM, 332 Da) in phosphate buffered saline were formed in a DOPC/dodecane suspension (1 mM). Output vesicles were collected and tested for permeability and lamellarity using S. aureus α-hemolysin toxin (50 µg/mL, Sigma-Aldrich, St. Louis, MO). Two-color confocal fluorescence imaging microscopy time courses of both the dextran size exclusion marker (λ ex /λ em = 400 nm/420 nm) and the small molecule fluorescein dye (490 nm/520 nm) were acquired (FV1000, Olympus, Center Valley, PA), and intensity and sizing data were quantitated (ImageJ, NIH, Bethesda, MD). Fluorescence data following hemolysin treatment were normalized to the pre-treatment intensity. DIC imaging was conducted using an oil immersion objective (40X 1.3 NA, Olympus).
Encapsulation yields were measured by dividing the fluorescence intensity of a product vesicle after phase transfer by the fluorescence intensity of the droplet just prior to phase transfer. Encapsulation yield was calculated for each vesicle assembly event.
Fluorescein photobleaching and vesicle integrity were assessed by monitoring the time 
